Hodgkin, Low-Risk Disease Study - Phase III

Treatment of Children and Adolescents Newly Diagnosed with Low-Risk Hodgkin's Disease

Protocol Description

The primary purpose of this Children's Oncology Group Phase III study is to learn more about Hodgkin disease, one of the most treatable and curable childhood cancers. Study goals are: 1) determine if participants who respond well to chemotherapy alone can be treated successfully without radiation therapy; and 2) determine if participants who relapse after chemotherapy alone can be treated successfully with less intensive treatment than the current standard relapse treatment. About 400 male and female participants under the age of 21 will take part in this multi-center study.

Eligibility Criteria

Eligible candidates include boys and girls under the age of 21 with Hodgkin disease.
Boys: up to age 21
Girls: up to age 21

Participants begin treatment with three 21-day cycles of anti-cancer drugs. If the disease goes away after these cycles, participants do not require more treatment. If the disease does not go away, they receive radiation therapy. If the disease gets worse, they are taken off the study therapy. If chemotherapy resolves the condition, but it comes back in a low-risk relapse, participants may join the relapse part of the study.
Visits: Minimum of three 21-day cycles
Duration: Dependent on the child’s response to treatment. Participants will be followed for at least 5 years after treatment.

Status: Open for Enrollment

Source of Support
Children’s Oncology Group
National Cancer Institute

Additional Resources
Study Description at National Institutes of Health

Primary Investigator(s)

Peter H. Shaw, MD

Contact Information

To get started, please contact:
Peter H. Shaw, MD

Last Update
January 7, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
January 7, 2014